Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EBITDA (2018 - 2025)

Inmune Bio (INMB) has disclosed EBITDA for 8 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 40.2% to -$5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$46.1 million through Dec 2025, down 10.12% year-over-year, with the annual reading at -$46.1 million for FY2025, 10.12% down from the prior year.
  • EBITDA hit -$5.2 million in Q4 2025 for Inmune Bio, up from -$6.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$4.6 million in Q1 2021 to a low of -$24.6 million in Q2 2025.
  • Historically, EBITDA has averaged -$8.8 million across 5 years, with a median of -$8.3 million in 2022.
  • Biggest five-year swings in EBITDA: tumbled 224.65% in 2021 and later soared 47.87% in 2025.
  • Year by year, EBITDA stood at -$9.6 million in 2021, then soared by 43.57% to -$5.4 million in 2022, then tumbled by 57.18% to -$8.5 million in 2023, then decreased by 3.36% to -$8.8 million in 2024, then surged by 40.2% to -$5.2 million in 2025.
  • Business Quant data shows EBITDA for INMB at -$5.2 million in Q4 2025, -$6.5 million in Q3 2025, and -$24.6 million in Q2 2025.